Evidence map›Paper›PMID 26621741›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Claire M Faltermeier, Justin M Drake, Peter M Clark, Bryan A Smith, Yang Zong, Carmen Volpe, Colleen Mathis, Colm Morrissey, Brandon Castor, Jiaoti Huang and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. ATAD2 Drives Prostate Cancer Progression to Metastasis.Molecular cancer research : MCR · 2025
    Article
  6. Article
  7. Review
  8. The Role of TAM Receptors in Bone.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Article
  16. Article
  17. Interception Targets ofCancer prevention research (Philadelphia, Pa.) · 2021
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Claire M FaltermeierMolecular Biology Institute, University of California, Los Angeles, CA 90095;
Justin M DrakeDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095;
Peter M ClarkDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095;
Bryan A SmithDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095;
Yang ZongHoward Hughes Medical Institute, University of California, Los Angeles, CA 90095;
Carmen VolpeDivision of Laboratory and Animal Medicine, University of California, Los Angeles, CA 90095;
Colleen MathisDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095;
Colm MorrisseyDepartment of Urology, University of Washington, Seattle, WA 98195;
Brandon CastorDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095;
Jiaoti HuangDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095; Department of Urology, University of California, Los Angeles, CA 90095; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095; David Geffen School of Medicine, University of California, Los Angeles, CA 90095; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095.
Owen N WitteMolecular Biology Institute, University of California, Los Angeles, CA 90095; Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095; Howard Hughes Medical Institute, University of California, Los Angeles, CA 90095; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095; David Geffen School of Medicine, University of California, Los Angeles, CA 90095; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095 owenwitte@mednet.ucla.edu.
University of California, Los Angeles · USHoward Hughes Medical Institute · USUniversity of Washington · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Transductionally Redirected /Transcriptionally RestricteP50CA086306 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HERSCHMAN, HARVEY R. · 2000 to 2014
$29.0M
Transmembrane Proteases and Prostate CarcinogenesisP01CA085859 · NCI · UNIVERSITY OF WASHINGTON · PI VESSELLA, ROBERT LOUIS · 2002 to 2013
$21.2M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
UCLA Scholars in Oncologic Molecular lmaging (SOMI)R25CA098010 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PHELPS, MICHAEL E · 2003 to 2013
$5.0M
Identification of DNA methylation markers for risk of metastasis in localized proR01CA181242 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHAO, CHUN R. · 2015 to 2019
$3.0M
A novel strategy to identify prostate cancer biomarkers for patient managementR01CA172603 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HUANG, JIAOTI · 2013 to 2017
$1.6M
Prospective Assessment of Image Registration for the Diagnosis of Prostate CancerR01CA195505 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARKS, LEONARD STEPHEN · 2015 to 2016
$705k
Howard Hughes Medical InstituteNCI NIH HHS 1R01CA181242-01A1NCI NIH HHS 1R01CA195505NCI NIH HHS 2P30CA016042-39NCI NIH HHS 5R01CA172603-02NCI NIH HHS P01 CA085859NCI NIH HHS P01CA085859NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA086306NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA097186NCI NIH HHS P50CA97186NCI NIH HHS R01 CA172603NCI NIH HHS R01 CA181242NCI NIH HHS R01 CA195505NCI NIH HHS R25 CA098010NCI NIH HHS R25T CA098010NCI NIH HHS T32 CA009056NCI NIH HHS T32 CA00912NCI NIH HHS T32 CA009120
6 · The paper itself

Abstract

Mutationally activated kinases play an important role in the progression and metastasis of many cancers. Despite numerous oncogenic alterations implicated in metastatic prostate cancer, mutations of kinases are rare. Several lines of evidence suggest that nonmutated kinases and their pathways are involved in prostate cancer progression, but few kinases have been mechanistically linked to metastasis. Using a mass spectrometry-based phosphoproteomics dataset in concert with gene expression analysis, we selected over 100 kinases potentially implicated in human metastatic prostate cancer for functional evaluation. A primary in vivo screen based on overexpression of candidate kinases in murine prostate cells identified 20 wild-type kinases that promote metastasis. We queried these 20 kinases in a secondary in vivo screen using human prostate cells. Strikingly, all three RAF family members, MERTK, and NTRK2 drove the formation of bone and visceral metastasis confirmed by positron-emission tomography combined with computed tomography imaging and histology. Immunohistochemistry of tissue microarrays indicated that these kinases are highly expressed in human metastatic castration-resistant prostate cancer tissues. Our functional studies reveal the strong capability of select wild-type protein kinases to drive critical steps of the metastatic cascade, and implicate these kinases in possible therapeutic intervention.

Indexed as

AnimalsBone and BonesBone NeoplasmsCell Line, TumorGene Expression ProfilingHumansLentivirusLungMaleMiceMice, SCIDNeoplasm ProteinsPhosphoproteinsProstatic NeoplasmsProtein KinasesProteomicsNeoplasm ProteinsPhosphoproteinsProtein Kinasessrc-Family Kinasesbone metastasiskinasesmetastasisprostate cancer

Identifiers

PMID26621741
PMCPMC4720329
OpenAlexW2187669846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.